Phong Phu Pharmaceutical JSC (HNX:PPP)
Vietnam · Delayed Price · Currency is VND 18,500
+100 (0.54%)
At close: Aug 12, 2026
HNX:PPP Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 153,343 | 139,740 | 137,548 | 152,172 | 150,575 | 133,289 | |
Revenue Growth | 12.85% | 1.59% | -9.61% | 1.06% | 12.97% | 14.65% |
Cost of Revenue | 95,422 | 90,411 | 91,144 | 103,016 | 99,285 | 88,053 |
Gross Profit | 57,921 | 49,329 | 46,404 | 49,156 | 51,290 | 45,237 |
Selling, General & Admin | 29,338 | 28,129 | 26,149 | 26,046 | 26,096 | 25,543 |
Operating Expenses | 29,338 | 28,129 | 26,149 | 26,046 | 26,096 | 25,543 |
Operating Income | 28,584 | 21,200 | 20,255 | 23,110 | 25,194 | 19,693 |
Interest Expense | -182.64 | -85.17 | - | - | -45.36 | -434.42 |
Interest & Investment Income | 1,718 | 1,718 | 1,390 | 1,327 | 561.01 | 109.53 |
Currency Exchange Gain (Loss) | -30.39 | -30.39 | -0.96 | -1.46 | - | - |
Other Non Operating Income (Expenses) | 7,006 | 394.17 | 143.82 | 150.99 | 93.21 | 77.97 |
EBT Excluding Unusual Items | 37,095 | 23,197 | 21,788 | 24,587 | 25,802 | 19,446 |
Gain (Loss) on Sale of Assets | - | - | 22.35 | 0.94 | - | - |
Pretax Income | 37,095 | 23,197 | 21,810 | 24,588 | 25,802 | 19,446 |
Income Tax Expense | 7,440 | 4,642 | 4,451 | 4,486 | 5,191 | 2,553 |
Net Income | 29,655 | 18,555 | 17,359 | 20,102 | 20,611 | 16,893 |
Preferred Dividends & Other Adjustments | 1,983 | 1,983 | 1,812 | 1,964 | - | - |
Net Income to Common | 27,671 | 16,571 | 15,548 | 18,138 | 20,611 | 16,893 |
Net Income Growth | 61.12% | 6.59% | -14.28% | -12.00% | 22.01% | 72.11% |
Shares Outstanding (Basic) | 9 | 9 | 9 | 9 | 10 | 10 |
Shares Outstanding (Diluted) | 9 | 9 | 9 | 9 | 10 | 10 |
Shares Change | -0.77% | - | - | -9.83% | -0.34% | -0.72% |
EPS (Basic) | 3163.55 | 1883.11 | 1766.77 | 2061.13 | 2112.00 | 1725.00 |
EPS (Diluted) | 3163.55 | 1883.11 | 1766.77 | 2061.13 | 2112.00 | 1725.00 |
EPS Growth | 62.37% | 6.59% | -14.28% | -2.41% | 22.43% | 73.37% |
Free Cash Flow | 28,111 | 15,272 | 16,787 | 17,428 | 20,117 | 18,129 |
Free Cash Flow Per Share | 3213.78 | 1735.44 | 1907.56 | 1980.47 | 2061.38 | 1851.27 |
Dividend Per Share | - | - | 1500.000 | 1200.000 | 1400.000 | - |
Dividend Growth | - | - | 25.00% | -14.29% | - | - |
Gross Margin | 37.77% | 35.30% | 33.74% | 32.30% | 34.06% | 33.94% |
Operating Margin | 18.64% | 15.17% | 14.73% | 15.19% | 16.73% | 14.77% |
Profit Margin | 18.05% | 11.86% | 11.30% | 11.92% | 13.69% | 12.67% |
Free Cash Flow Margin | 18.33% | 10.93% | 12.20% | 11.45% | 13.36% | 13.60% |
EBITDA | 32,752 | 25,336 | 24,468 | 27,926 | 31,419 | 25,871 |
EBITDA Margin | 21.36% | 18.13% | 17.79% | 18.35% | 20.87% | 19.41% |
D&A For EBITDA | 4,169 | 4,136 | 4,213 | 4,816 | 6,225 | 6,178 |
EBIT | 28,584 | 21,200 | 20,255 | 23,110 | 25,194 | 19,693 |
EBIT Margin | 18.64% | 15.17% | 14.73% | 15.19% | 16.73% | 14.77% |
Effective Tax Rate | 20.06% | 20.01% | 20.41% | 18.25% | 20.12% | 13.13% |
Revenue as Reported | 153,343 | 139,740 | 137,548 | 152,172 | 150,575 | 133,289 |
Advertising Expenses | - | 268.7 | 490.39 | 285.73 | - | - |